中国药业
中國藥業
중국약업
China Pharmaceuticals
2015年
19期
91-92,93
,共3页
西格列汀%二甲双胍%老年%2型糖尿病
西格列汀%二甲雙胍%老年%2型糖尿病
서격렬정%이갑쌍고%노년%2형당뇨병
sitagliptin%metformin%elderly%type 2 diabetes mellitus
目的：探讨西格列汀联合二甲双胍治疗老年2型糖尿病( T2DM )的临床疗效及安全性。方法选取2014年1月至2015年1月收治的老年T2DM患者90例，随机分为观察组和对照组，各45例，两组患者均予饮食、运动等生活方式干预，并根据病情应用控制血压、血脂药物，对照组给予盐酸二甲双胍，观察组在对照组基础上联用西格列汀，均连续用药3个月为1个疗程。结果治疗后，两组患者体重指数（BMI）较治疗前无明显变化（ P﹥0.05），血糖参数[空腹血糖（FPG）、餐后两小时血糖（2 h PG）、糖化血红蛋白（HbA1C )]较治疗前均有下降，与对照组相比，观察组血糖参数改善更显著（ P﹤0.05）。与治疗前比较，两组患者胰岛素敏感指数（HOMA－IS）、胰岛β细胞功能（HOMA－β）均显著升高，且观察组改善较对照组更明显（ P﹤0.05）。治疗过程中，两组患者肝、肾功能均未出现异常，不良反应均较轻微，发生率无统计学差异（ P﹥0.05）。结论西格列汀联合二甲双胍治疗老年T2DM较单用二甲双胍治疗能更有效地控制血糖，提高胰岛素敏感性，保护β细胞功能，降低不良反应的发生率，具有临床推广意义。
目的：探討西格列汀聯閤二甲雙胍治療老年2型糖尿病( T2DM )的臨床療效及安全性。方法選取2014年1月至2015年1月收治的老年T2DM患者90例，隨機分為觀察組和對照組，各45例，兩組患者均予飲食、運動等生活方式榦預，併根據病情應用控製血壓、血脂藥物，對照組給予鹽痠二甲雙胍，觀察組在對照組基礎上聯用西格列汀，均連續用藥3箇月為1箇療程。結果治療後，兩組患者體重指數（BMI）較治療前無明顯變化（ P﹥0.05），血糖參數[空腹血糖（FPG）、餐後兩小時血糖（2 h PG）、糖化血紅蛋白（HbA1C )]較治療前均有下降，與對照組相比，觀察組血糖參數改善更顯著（ P﹤0.05）。與治療前比較，兩組患者胰島素敏感指數（HOMA－IS）、胰島β細胞功能（HOMA－β）均顯著升高，且觀察組改善較對照組更明顯（ P﹤0.05）。治療過程中，兩組患者肝、腎功能均未齣現異常，不良反應均較輕微，髮生率無統計學差異（ P﹥0.05）。結論西格列汀聯閤二甲雙胍治療老年T2DM較單用二甲雙胍治療能更有效地控製血糖，提高胰島素敏感性，保護β細胞功能，降低不良反應的髮生率，具有臨床推廣意義。
목적：탐토서격렬정연합이갑쌍고치료노년2형당뇨병( T2DM )적림상료효급안전성。방법선취2014년1월지2015년1월수치적노년T2DM환자90례，수궤분위관찰조화대조조，각45례，량조환자균여음식、운동등생활방식간예，병근거병정응용공제혈압、혈지약물，대조조급여염산이갑쌍고，관찰조재대조조기출상련용서격렬정，균련속용약3개월위1개료정。결과치료후，량조환자체중지수（BMI）교치료전무명현변화（ P﹥0.05），혈당삼수[공복혈당（FPG）、찬후량소시혈당（2 h PG）、당화혈홍단백（HbA1C )]교치료전균유하강，여대조조상비，관찰조혈당삼수개선경현저（ P﹤0.05）。여치료전비교，량조환자이도소민감지수（HOMA－IS）、이도β세포공능（HOMA－β）균현저승고，차관찰조개선교대조조경명현（ P﹤0.05）。치료과정중，량조환자간、신공능균미출현이상，불량반응균교경미，발생솔무통계학차이（ P﹥0.05）。결론서격렬정연합이갑쌍고치료노년T2DM교단용이갑쌍고치료능경유효지공제혈당，제고이도소민감성，보호β세포공능，강저불량반응적발생솔，구유림상추엄의의。
Objective To investigate the clinical efficacy and safety of sitagliptin combined with metformin in treating type 2 diabetes mellitus ( T2DM ) . Methods 90 cases of patient during Jan 2014 to Jan 2015 were randomly divided into the control group and the observation group, 45 cases in each group. The two groups were given life style intervention such as diet and exercise, and the applica-tion of hypertension drugs and hypolipidemic drugs according to the conditions. The control group was given metformin hydrochloride;on the basis of the control group, the observation group was given sitagliptin. Two groups of patients were treated for 3 months for 1 course of treatment. Results After treatment, the BMI index in two groups had no significant improvement ( P ﹥ 0. 05 ) . Compared with those before treatment, the blood parameters of FPG, 2 hPG, HbA1C of the two groups decreased, and the decrease in the observation group was more significant( P ﹤ 0. 05). Compared with before treatment, the HOMA-IS and HOMA-beta of the two groups were significantly in-creased ( P ﹤ 0. 05 ) , and the increase in the observation group was more significant. The liver and renal function were normal in the two groups, and the adverse reactions of the two groups were mild with no significant difference between the two groups ( P ﹥ 0. 05 ) . Conclusion Compared with applying only metformin, sitagliptin combined with metformin in treating elderly type 2 diabetes mellitus can more effectively control blood sugar, improve insulin sensitivity, protect the beta cell function, reduce the incidence of adverse reactions and is worthy of clinical promotion.
